HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wojciech Woźniak Selected Research

Therapeutics

1/2014[Evaluation of selected parameters of specific immunity in children with osteosarcoma at various stages of antitumour treatment].
7/2010[A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis].
7/2009[Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study].
7/2005[Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group].
4/2004[Biochemical bone resorption markers in children with osteosarcoma].
4/2004[Cytometric analysis of the relation between aneuploidy and expression of receptors for insulin growth factor I in child and adolescent osteosarcoma, after preliminary chemotherapy].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wojciech Woźniak Research Topics

Disease

13Osteosarcoma (Osteogenic Sarcoma)
01/2014 - 01/2004
5Neoplasms (Cancer)
04/2013 - 04/2004
4Disease Progression
07/2009 - 04/2004
2Neoplasm Metastasis (Metastasis)
01/2011 - 04/2004
2Bone Resorption
07/2010 - 04/2004
2Aneuploidy (Aneuploid)
10/2004 - 04/2004
1Immune System Diseases (Immune Disorders)
01/2014
1Leukopenia
01/2014
1Ewing Sarcoma (Sarcoma, Ewing)
04/2013
1Sepsis (Septicemia)
07/2007
1Neutropenia
07/2007
1Wounds and Injuries (Trauma)
05/2007
1Thyroid Neoplasms (Thyroid Cancer)
01/2006
1Sarcoma (Soft Tissue Sarcoma)
07/2005
1Fanconi Syndrome (Syndrome, Fanconi)
04/2004
1Acidosis
04/2004
1Bone Diseases (Bone Disease)
04/2004

Drug/Important Bio-Agent (IBA)

4DNA (Deoxyribonucleic Acid)IBA
10/2004 - 04/2004
3Cytostatic AgentsIBA
01/2014 - 10/2004
2Biomarkers (Surrogate Marker)IBA
01/2011 - 04/2004
2collagen type I trimeric cross-linked peptideIBA
10/2006 - 04/2004
2Collagen Type I (Type I Collagen)IBA
10/2006 - 04/2004
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2004 - 04/2004
2Insulin-Like Growth Factor I (IGF-1)IBA
04/2004 - 04/2004
1Antineoplastic Agents (Antineoplastics)IBA
01/2014
1Pharmaceutical PreparationsIBA
10/2013
1Methotrexate (Mexate)FDA LinkGeneric
10/2013
1Cisplatin (Platino)FDA LinkGeneric
04/2013
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2013
1Doxorubicin (Adriamycin)FDA LinkGeneric
04/2013
1Irinotecan (Camptosar)FDA LinkGeneric
04/2013
1Teniposide (VM 26)FDA Link
04/2013
1Temozolomide (Temodar)FDA LinkGeneric
04/2013
1Vincristine (Oncovin)FDA LinkGeneric
04/2013
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2011
1ML 7IBA
07/2009
1human ERBB2 proteinIBA
07/2009
1Monoclonal AntibodiesIBA
07/2009
1OsteocalcinIBA
10/2006
1Alkaline PhosphataseIBA
10/2006
1Biological ProductsIBA
01/2006
1Insulin (Novolin)FDA Link
04/2004
1IfosfamideFDA LinkGeneric
04/2004
1ElectrolytesIBA
04/2004
1CollagenIBA
04/2004
1OsteoprotegerinIBA
04/2004

Therapy/Procedure

11Drug Therapy (Chemotherapy)
01/2014 - 01/2004
6Therapeutics
01/2014 - 04/2004
3Aftercare (After-Treatment)
10/2006 - 04/2004
1Sutures (Suture)
05/2007